Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients

Myron F. Weiner, Kristin Martin-Cook, Barbara M. Foster, Kathleen Saine, Catherine S. Fontaine, Doris A. Svetlik

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background: This open-label study examined the effects of the reversible cholinesterase inhibitor donepezil on emotional/behavioral symptoms in Alzheimer's disease (AD) patients. Method: Patients were diagnosed as having probable/possible AD by National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria. This study used the CERAD Behavior Rating Scale for Dementia (CBRSD) and its subscales to evaluate a group of 25 AD patients treated with donepezil. Dosage was increased at 4 months for most patients from 5 to 10 mg q.h.s. Analysis of variance was used to compare scores over a period of 12 months. These patients were also compared, using t tests, to a reference group that had received no donepezil or other anticholinesterase. Results: Donepezil administration was associated with improvement in Mini- Mental State Examination (MMSE) and CBRSD total scores at 3-month evaluation (p ≤ .05). CBRSD depression and behavioral dysregulation scores improved transiently at 4 months (p ≤ .05). MMSE, CBRSD total, CBRSD depression, and CBRSD behavioral dysregulation scores returned to baseline levels at 12 months, in contrast to the reference group, whose MMSE and CBRSD total scores worsened minimally over the 12 months. Conclusion: Donepezil has a mildly positive effect on emotional/behavioral symptoms in AD in addition to its effect on cognitive function.

Original languageEnglish (US)
Pages (from-to)487-492
Number of pages6
JournalJournal of Clinical Psychiatry
Volume61
Issue number7
StatePublished - Jul 2000

Fingerprint

Behavioral Symptoms
Dementia
Alzheimer Disease
Cholinesterase Inhibitors
National Institute of Neurological Disorders and Stroke
Depression
Communication Disorders
donepezil
Behavior Rating Scale
Cognition
Analysis of Variance

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Weiner, M. F., Martin-Cook, K., Foster, B. M., Saine, K., Fontaine, C. S., & Svetlik, D. A. (2000). Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. Journal of Clinical Psychiatry, 61(7), 487-492.

Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. / Weiner, Myron F.; Martin-Cook, Kristin; Foster, Barbara M.; Saine, Kathleen; Fontaine, Catherine S.; Svetlik, Doris A.

In: Journal of Clinical Psychiatry, Vol. 61, No. 7, 07.2000, p. 487-492.

Research output: Contribution to journalArticle

Weiner, MF, Martin-Cook, K, Foster, BM, Saine, K, Fontaine, CS & Svetlik, DA 2000, 'Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients', Journal of Clinical Psychiatry, vol. 61, no. 7, pp. 487-492.
Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS, Svetlik DA. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. Journal of Clinical Psychiatry. 2000 Jul;61(7):487-492.
Weiner, Myron F. ; Martin-Cook, Kristin ; Foster, Barbara M. ; Saine, Kathleen ; Fontaine, Catherine S. ; Svetlik, Doris A. / Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. In: Journal of Clinical Psychiatry. 2000 ; Vol. 61, No. 7. pp. 487-492.
@article{466984d36f7f4219879767273e140107,
title = "Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients",
abstract = "Background: This open-label study examined the effects of the reversible cholinesterase inhibitor donepezil on emotional/behavioral symptoms in Alzheimer's disease (AD) patients. Method: Patients were diagnosed as having probable/possible AD by National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria. This study used the CERAD Behavior Rating Scale for Dementia (CBRSD) and its subscales to evaluate a group of 25 AD patients treated with donepezil. Dosage was increased at 4 months for most patients from 5 to 10 mg q.h.s. Analysis of variance was used to compare scores over a period of 12 months. These patients were also compared, using t tests, to a reference group that had received no donepezil or other anticholinesterase. Results: Donepezil administration was associated with improvement in Mini- Mental State Examination (MMSE) and CBRSD total scores at 3-month evaluation (p ≤ .05). CBRSD depression and behavioral dysregulation scores improved transiently at 4 months (p ≤ .05). MMSE, CBRSD total, CBRSD depression, and CBRSD behavioral dysregulation scores returned to baseline levels at 12 months, in contrast to the reference group, whose MMSE and CBRSD total scores worsened minimally over the 12 months. Conclusion: Donepezil has a mildly positive effect on emotional/behavioral symptoms in AD in addition to its effect on cognitive function.",
author = "Weiner, {Myron F.} and Kristin Martin-Cook and Foster, {Barbara M.} and Kathleen Saine and Fontaine, {Catherine S.} and Svetlik, {Doris A.}",
year = "2000",
month = "7",
language = "English (US)",
volume = "61",
pages = "487--492",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "7",

}

TY - JOUR

T1 - Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients

AU - Weiner, Myron F.

AU - Martin-Cook, Kristin

AU - Foster, Barbara M.

AU - Saine, Kathleen

AU - Fontaine, Catherine S.

AU - Svetlik, Doris A.

PY - 2000/7

Y1 - 2000/7

N2 - Background: This open-label study examined the effects of the reversible cholinesterase inhibitor donepezil on emotional/behavioral symptoms in Alzheimer's disease (AD) patients. Method: Patients were diagnosed as having probable/possible AD by National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria. This study used the CERAD Behavior Rating Scale for Dementia (CBRSD) and its subscales to evaluate a group of 25 AD patients treated with donepezil. Dosage was increased at 4 months for most patients from 5 to 10 mg q.h.s. Analysis of variance was used to compare scores over a period of 12 months. These patients were also compared, using t tests, to a reference group that had received no donepezil or other anticholinesterase. Results: Donepezil administration was associated with improvement in Mini- Mental State Examination (MMSE) and CBRSD total scores at 3-month evaluation (p ≤ .05). CBRSD depression and behavioral dysregulation scores improved transiently at 4 months (p ≤ .05). MMSE, CBRSD total, CBRSD depression, and CBRSD behavioral dysregulation scores returned to baseline levels at 12 months, in contrast to the reference group, whose MMSE and CBRSD total scores worsened minimally over the 12 months. Conclusion: Donepezil has a mildly positive effect on emotional/behavioral symptoms in AD in addition to its effect on cognitive function.

AB - Background: This open-label study examined the effects of the reversible cholinesterase inhibitor donepezil on emotional/behavioral symptoms in Alzheimer's disease (AD) patients. Method: Patients were diagnosed as having probable/possible AD by National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria. This study used the CERAD Behavior Rating Scale for Dementia (CBRSD) and its subscales to evaluate a group of 25 AD patients treated with donepezil. Dosage was increased at 4 months for most patients from 5 to 10 mg q.h.s. Analysis of variance was used to compare scores over a period of 12 months. These patients were also compared, using t tests, to a reference group that had received no donepezil or other anticholinesterase. Results: Donepezil administration was associated with improvement in Mini- Mental State Examination (MMSE) and CBRSD total scores at 3-month evaluation (p ≤ .05). CBRSD depression and behavioral dysregulation scores improved transiently at 4 months (p ≤ .05). MMSE, CBRSD total, CBRSD depression, and CBRSD behavioral dysregulation scores returned to baseline levels at 12 months, in contrast to the reference group, whose MMSE and CBRSD total scores worsened minimally over the 12 months. Conclusion: Donepezil has a mildly positive effect on emotional/behavioral symptoms in AD in addition to its effect on cognitive function.

UR - http://www.scopus.com/inward/record.url?scp=0033929454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033929454&partnerID=8YFLogxK

M3 - Article

C2 - 10937606

AN - SCOPUS:0033929454

VL - 61

SP - 487

EP - 492

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 7

ER -